X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (42) 42
humans (35) 35
oncology (33) 33
cancer (29) 29
male (27) 27
middle aged (27) 27
female (24) 24
adult (23) 23
aged (23) 23
metastasis (18) 18
chemotherapy (14) 14
tumors (14) 14
life sciences (13) 13
treatment outcome (12) 12
aged, 80 and over (11) 11
antineoplastic agents - therapeutic use (11) 11
prognosis (11) 11
thyroid neoplasms - drug therapy (11) 11
survival (10) 10
carcinoma (9) 9
colorectal cancer (9) 9
disease-free survival (9) 9
medical prognosis (9) 9
sorafenib (9) 9
survival analysis (9) 9
thyroid cancer (9) 9
thyroid neoplasms - pathology (9) 9
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
care and treatment (8) 8
cisplatin (8) 8
clinical trials (8) 8
mutation (8) 8
retrospective studies (8) 8
5-fluorouracil (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
cancer therapies (7) 7
gemcitabine (7) 7
kaplan-meier estimate (7) 7
metastases (7) 7
neoplasm metastasis (7) 7
papillary (7) 7
patients (7) 7
therapy (7) 7
adenocarcinoma (6) 6
endocrinology & metabolism (6) 6
management (6) 6
multicenter (6) 6
phase-ii trial (6) 6
surgery (6) 6
young adult (6) 6
abridged index medicus (5) 5
adenocarcinoma, follicular - drug therapy (5) 5
analysis (5) 5
antineoplastic agents - adverse effects (5) 5
camptothecin - administration & dosage (5) 5
camptothecin - analogs & derivatives (5) 5
colorectal neoplasms - drug therapy (5) 5
colorectal neoplasms - pathology (5) 5
diagnosis (5) 5
drug therapy (5) 5
fluorouracil (5) 5
genetics (5) 5
hematology, oncology and palliative medicine (5) 5
human health and pathology (5) 5
oxaliplatin (5) 5
pancreatic neoplasms - pathology (5) 5
phenylurea compounds - therapeutic use (5) 5
solid tumors (5) 5
studies (5) 5
sunitinib (5) 5
thyroid neoplasms - mortality (5) 5
adenocarcinoma - drug therapy (4) 4
adenocarcinoma - pathology (4) 4
adenocarcinoma - secondary (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
biomarkers (4) 4
cancer research (4) 4
cetuximab (4) 4
combination (4) 4
deoxycytidine - analogs & derivatives (4) 4
docetaxel (4) 4
double-blind (4) 4
fluorouracil - administration & dosage (4) 4
further section (4) 4
indoles - therapeutic use (4) 4
irinotecan (4) 4
leucovorin (4) 4
metastatic colorectal cancer (4) 4
organoplatinum compounds - administration & dosage (4) 4
pancreas (4) 4
pancreatic cancer (4) 4
pancreatic neoplasms - drug therapy (4) 4
phenylurea compounds - administration & dosage (4) 4
pyrroles - therapeutic use (4) 4
radiation therapy (4) 4
regorafenib (4) 4
research (4) 4
thyroid carcinoma (4) 4
toxicity (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 01/2020, Volume 23, Issue 1, p. 73
The correlation between immune cells and the Lauren classification subtypes and their prognostic impact in advanced gastric cancer (AGC) are unknown.... 
Journal Article
The Oncologist, ISSN 1083-7159, 12/2019, Volume 24, Issue 12, pp. 1543 - 1548
Background Metastatic pancreatic ductal adenocarcinoma (mPDAC) is an aggressive malignancy with a median overall survival (OS) of between 8 and 11 months.... 
Long‐term survivors | Metastasis | Survival | Pancreatic ductal adenocarcinoma | Prognostic factors
Journal Article
The Oncologist, ISSN 1083-7159, 12/2019, Volume 24, Issue 12, pp. e1331 - e1340
Background BRAFV600E mutations occurring in about 10% of metastatic colorectal cancers (mCRCs) are usually associated with a poor outcome. However, their... 
BRAF | Decision making | Prognostic | Colorectal cancer | Mismatch repair testing
Journal Article
ANNALS OF TRANSLATIONAL MEDICINE, ISSN 2305-5839, 11/2019, Volume 7, Issue 21, pp. 601 - 601
Journal Article
Bulletin du cancer, 09/2019, Volume 106, Issue 9, p. 812
Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC) represent a challenging subgroup of DTC because they are at higher risk of... 
Journal Article
BULLETIN DU CANCER, ISSN 0007-4551, 09/2019, Volume 106, Issue 9, pp. 812 - 819
Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC) represent a challenging subgroup of DTC because they are at higher risk of... 
THYROGLOBULIN DOUBLING TIME | MANAGEMENT | TUTHYREF | BONE METASTASES | Target therapy | MULTICENTER PHASE-II | Radioiodine-refractory differentiated thyroid carcinoma | ZOLEDRONIC ACID | LENVATINIB | ONCOLOGY | Network | DOUBLE-BLIND | TYROSINE KINASE INHIBITOR | Molecular biology | Antiangiogenic | RADIOACTIVE IODINE | CLINICAL-OUTCOMES
Journal Article
Current Oncology, ISSN 1198-0052, 08/2019, Volume 26, Issue 4, pp. e466 - e472
Background Peritoneal carcinomatosis (PCM) in metastatic pancreatic ductal adenocarcinomas (mPDAC) is frequently encountered in day-to-day practice, but rarely... 
pancreatic cancer | Prognosis | metastatic sites | Original | peritoneal carcinomatosis
Journal Article
Journal Article
The oncologist, 05/2019
mutations occurring in about 10% of metastatic colorectal cancers (mCRCs) are usually associated with a poor outcome. However, their prognostic factors are... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 757 - 765
Abstract Background Antitumor activity of molecular-targeted agents is guided by the presence of documented genomic alteration in specific histological... 
precision medicine | molecular-targeted agents | advanced cancer | decision-making | molecular profiling | MULTICENTER | GENOMICS | ONCOLOGY | MEDICINE | Life Sciences
Journal Article
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 03/2019, Volume 37, Issue 8, pp. 658 - 658
PURPOSENo standard adjuvant treatment currently is recommended in localized biliary tract cancer (BTC) after surgical resection. We aimed to assess whether... 
CETUXIMAB | MULTICENTER | CLINICAL-TRIAL | CISPLATIN | ONCOLOGY | OPEN-LABEL | COMBINATION | CARCINOMA
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2019, Volume 37, Issue 4_suppl, pp. 638 - 638
638 Background: Pivotal RECOURSE trial assessed efficacy and safety of trifluridine/tipiracil (FTD/TPI) in mCRC patients (pts) without collecting QoL data.... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.